News
SNY
48.23
-0.47%
-0.23
Trump Weekly: Furniture tariffs delayed, drugmakers hike prices
TipRanks · 9h ago
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
NASDAQ · 14h ago
Midday Fly By: Nvidia said to see strong H200 demand in China
TipRanks · 12/31/2025 17:00
Pfizer (PFE) Tops List as Drugmakers Plan Price Hike on 350 Medications
TipRanks · 12/31/2025 15:02
Trump Trade: 350 drugs to see price raises despite President’s pressure
TipRanks · 12/31/2025 14:55
Drugmakers raise U.S. prices on 350 drugs despite Trump pressure, Reuters says
TipRanks · 12/31/2025 14:00
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026
Benzinga · 12/31/2025 13:59
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Seeking Alpha · 12/31/2025 13:22
TG Therapeutics: What Wall Street Isn't Telling You
Seeking Alpha · 12/30/2025 16:00
Biotech Stocks Facing FDA Decision In January 2026
NASDAQ · 12/30/2025 08:21
TD Cowen Sticks to Their Hold Rating for Sanofi (SNY)
TipRanks · 12/30/2025 05:15
Sanofi to Buy Dynavax in $2.2 Billion Push Into Adult Vaccines
TipRanks · 12/29/2025 22:09
DYNAVAX TECHNOLOGIES CORP: IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES, SANOFI TO PAY CO REVERSE TERMINATION FEE OF $116.8 MLN
Reuters · 12/29/2025 12:34
Sanofi to Acquire Dynavax for $15.50 Per Share in Cash
Reuters · 12/29/2025 12:32
Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential
Seeking Alpha · 12/29/2025 12:00
Sanofi Hit by FDA Rebuff on Tolebrutinib MS Filing but Sees No Change to 2025 Outlook
TipRanks · 12/29/2025 11:46
Sanofi Wins EU Approval for Wayrilz as First BTK Inhibitor for Immune Thrombocytopenia
Reuters · 12/29/2025 11:23
Sanofi SA Conducts Impairment Test on Tolebrutinib Asset Value
Reuters · 12/29/2025 11:23
Weekly Report: what happened at SNY last week (1222-1226)?
Weekly Report · 12/29/2025 10:09
Sanofi (SNYNF) Gets a Buy from Jefferies
TipRanks · 12/29/2025 08:35
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.